

POET Technologies announce an Investor Day in Toronto and AGM details

POET Technologies Inc. {TSX.V: PTK} a developer of opto-electronics fabrication processes for the semiconductor industry, today announced that it will host an Investor Day for shareholders, stakeholders and analysts on May 17, 2016, and the AGM, on 7th July.

The investor day event will take place in Toronto, Canada, and the AGM in San Jose, California, USA.

SAN JOSE, Calif., May 04, 2016 **POET Technologies Inc. {TSX.V: PTK}** a developer of opto-electronics fabrication processes for the semiconductor industry, today announced that it will host an Investor Day for shareholders, stakeholders and analysts on May 17, 2016.

The event will be held at The Vintage Conservatory, Suite 102, 100 Lombard Street in Toronto, Ontario.

POET also announced that its Annual General and Special Meeting of Shareholders has been scheduled for July 7, 2016, in San Jose, CA.

POET's Investor Day will include a series of presentations by the Company's senior leadership team. Management presentations are scheduled to begin at 14:30 GMT and conclude at 16:30 GMT.

The presentation will also be webcast beginning at 19:30 GMT on May 17, 2016, and will be able to be accessed from POET's investor relations section of its website at www.poet-technologies.com

To listen to the live webcast, please visit this website approximately 15 minutes prior to the start of the event to register, download and install any necessary audio software. A replay will be available shortly after the presentation on the POET website for 90 days. Pre-submitted questions may be sent to rf@poet-technologies.com in advance until May 16, 2016. Expected topics to be covered include POET's strategic, development and commercialization initiatives.

The AGSM is scheduled for 9:00 a.m. PDT on Thursday, July 7, 2016, at the Courtyard San Jose Airport, 1727 Technology Drive, San Jose CA.

The Record Date for voting and receiving notice of the AGSM has been set at May 27, 2016. The Company will be using the "Notice and Access" method for this AGSM, whereby only a proxy or a voting instruction form ("VIF") will be mailed to the shareholders of the Company (the "Shareholders") and the Information Circular will be available for download from the Company's website at www.poet-technologies.com/agm

following the said mailing. A proxy or VIF will be mailed to the Shareholders on or about June 6, 2016 and will contain the details of the meeting and the instructions for downloading the Information Circular or requesting a hard copy.

The Company's Transfer Agent will be mailing a proxy to the Shareholders who hold their shares in their own names ("Registered Shareholders") and a VIF to the Shareholders who have consented to having their broker release the details of their shareholdings to the Company (known as Non Objecting Beneficial Owners or "NOBO Shareholders"). Shareholders will be able to vote online, by fax or by mail.

The Shareholders who have objected to having their information shared with the Company (known as Objecting Beneficial Owners or "OBO Shareholders") may, at the discretion of their broker, receive a VIF mailed by the broker or its agent. NOBO and OBO Shareholders will be required to return their VIF within the time frame, and in the manner, set out in the instructions contained in the VIF. If they wish to attend the AGSM and vote personally, they must appoint themselves as proxyholder before the cut-off time and date set-out in the VIF.

All proxy votes must be received by the Company's transfer agent no later than 12:00 noon (EDT) on July 5, 2016. Shareholders may want to contact their broker to verify whether they are on the NOBO or OBO list and, if desired, request a change of their status before the Record Date.

About POET Technologies Inc.

POET is a developer of opto-electronics fabrication processes. POET believes that the advanced opto-electronics fab processes platform enables substantial improvements in energy efficiency, component cost and size in the production of smart optical components, the engines driving applications ranging from data centers to consumer products. Silicon Valley-based POET's patented module-on-a-chip process, which integrates

digital, high-speed analog and optical devices on the same chip, is designed to serve as an industry standard for smart-system fabrication.

More information may be obtained at www.poet-technologies.com

ON BEHALF OF THE BOARD OF DIRECTORS

(signed) "John F. O'Donnell", Secretary

Zenyatta to raise \$2.9 million via a Rights Issue

Zenyatta Ventures {TSX.V: ZEN} announced that it will be offering rights to holders of its common shares at the close of business on the record date of May 13, 2016, on the basis of one right for each common share held.

Zenyatta Announces Rights Offering to Fund Ongoing Market & Business Development Programs

Positive Feedback From Global End-Users Concluded That Additional Samples for Scaled up Testing Is an Important Step for Further High-Purity Albany Graphite Product Development

Zenyatta Ventures {TSX.V: ZEN} announces that it will be offering rights to holders of its common shares at the close of business on the record date of May 13, 2016, on the basis of one right for each common share held.

Fifteen (15) Rights will entitle the holder to subscribe for one Common Share of Zenyatta upon payment of the subscription price of \$0.75 per Common Share (the "Exercise Price"). The Rights Offering will be conducted in Canada and to shareholders outside of Canada who are eligible under certain exemptions. Shareholders who are resident outside of Canada are requested to contact the Company for further details.

The Rights will trade on the TSX Venture Exchange under the symbol **ZEN.RT** commencing on May 11, 2016 and until 12:00 p.m. (Toronto time) on June 3, 2016. The Rights will expire at 5:00 p.m. (Toronto time) on June 3, 2016 (the "Expiry Time"), after which time unexercised Rights will be void and of no value. Shareholders who fully exercise their Rights will be entitled to subscribe for additional Common Shares, if available as a result of unexercised Rights prior to the Expiry Time, subject to certain limitations set out in Zenyatta's rights offering circular.

Details of the Rights Offering will be set out in the rights offering notice and rights offering circular which will be available under Zenyatta's profile at www.sedar.com

The rights offering notice and accompanying rights certificate will be mailed to each shareholder of Zenyatta as at the record date. Registered shareholders who wish to exercise

their Rights must forward the completed rights certificate, together with the applicable funds, to the rights agent, Capital Transfer Agency Inc., on or before the Expiry Time. Shareholders who own their Common Shares through an intermediary, such as a bank, trust company, securities dealer or broker, will receive materials and instructions from their intermediary. The Company will not issue or forward rights certificates to shareholders resident in a jurisdiction outside of Canada (the "Ineligible Holders"). The rights certificates of Ineligible Holders will be issued to and held on their behalf by Capital Transfer Agency Inc., who will, prior to the Expiry Time, attempt to sell the rights of Ineligible Holders on such dates and at such prices as it determines in its sole discretion.

There are currently 58,954,016 Common Shares of Zenyatta outstanding. If all of the Rights issued under the Rights Offering are validly exercised, a total of 3,930,268 Common Shares will be issued under the Rights Offering with gross proceeds of approximately \$2,945,000.

Zenyatta intends to use the net proceeds of the Rights Offering to further the positive market and business development program initiated over a year ago for validation of Albany graphite in high purity graphite applications. This will include production of additional high purity Albany graphite samples for testing by end-users, academic labs and third party testing facilities in Europe, North America and Asia under confidentiality agreements. Production of samples will also provide added insights into the scale up of the purification process with optimization analysis and potentially associated cost reductions. Many of these organizations were provided a small amount of purified graphite material. These tested samples provided a good

initial assessment and guidance for the potential of Albany graphite for various applications that included batteries, fuel cells, powder metallurgy and graphene. The positive feedback concluded that additional samples for scaled up testing is an important step for further development of Zenyatta's Albany graphite material as a substitute for existing synthetic graphite in use today.

Standby Commitment

In connection with the Rights Offering, Zenyatta will be entering into stand-by purchase agreements with investors and insiders in an amount to be determined. In consideration for providing the Stand-By Commitment, the Stand-By Purchasers will be granted that number of common share purchase warrants (the "Stand-By Warrants") equal to 25% of the Stand-By Shares purchased under the Stand-By Commitment. Each whole Stand-By Warrant entitles the holder to acquire one Common Share for a price equal to the Exercise Price until June 4, 2018.

A further announcement will be made regarding the standby commitment before filing the rights offering notice and rights offering circular under Zenyatta's profile at www.sedar.com

To find out more on Zenyatta Ventures Ltd., please visit www.zenyatta.ca

CAUTIONARY STATEMENT: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward looking information and Zenyatta

cautions readers that forward looking information is based on certain assumptions and risk factors that could cause actual results to differ materially from the expectations of Zenyatta included in this news release. This news release includes certain "forward-looking statements", which often, but not always, can be identified by the use of words such as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". These statements are based on information currently available to Zenyatta and Zenyatta provides no assurance that actual results will meet management's expectations. Forward-looking statements include estimates and statements with respect to Zenyatta's future plans, objectives or goals, to the effect that Zenyatta or management expects a stated condition or result to occur, including the expected timing for release of a pre-feasibility study, the expected uses for graphite in the future, and the future uses of the graphite from Zenyatta's Albany deposit. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, results of metallurgical processing, ongoing exploration, project development, reclamation and capital costs of Zenyatta's mineral properties, and Zenyatta's financial condition and prospects, could differ materially from those currently anticipated in such statements for many reasons such as, but are not limited to: failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the inability to identify target markets and satisfy the product criteria for such markets; the inability to complete a prefeasibility study; the inability to enter into offtake agreements with qualified purchasers; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets, inflation, changes in exchange rates; fluctuations in

commodity prices; delays in the development of projects; capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in Zenyatta's public documents filed on SEDAR. This list is not exhaustive of the factors that may affect any of Zenyatta's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on Zenyatta's forward-looking statements. Although Zenyatta believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zenyatta disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Contact:

Zenyatta Ventures Ltd.

info@zenyatta.ca

+1 7 346 1660

www.zenyatta.ca

Barkerville Gold Mines and

Williams Creek Gold have entered into a definitive arrangement agreement

Barkerville Gold Mines {BGM.V} and Williams Creek Gold {WCX.V} have entered into a definitive arrangement agreement.

Barkerville to issue 6.8 million shares to conclude the deal.

Barkerville Gold Mines {BGM.V} and Williams Creek Gold {WCX.V} have entered into a definitive arrangement agreement dated April 29, 2016.

Barkerville has agreed to issue an aggregate of 6.8 million common shares in exchange for all of the issued and outstanding common shares of Williams Creek. Williams Creek will become a wholly owned subsidiary of Barkerville and former shareholders of Williams Creek will hold approximately 2.27% of the shares of Barkerville on an outstanding basis.

The Transaction will be implemented by way of plan of arrangement and must be approved by two-thirds of the votes cast by shareholders present and voting at the special meeting of Williams Creek shareholders called to consider the Arrangement. Williams Creek is up 1 cent to 3 cents, within a 52-week range of \$0.005 – \$0.04 cents.

Barkerville Gold Mines is engaged in the exploration and production of mineral properties located in the Cariboo Mining

District in east-central British Columbia. The company has a market cap of \$140.45 million. The Firm controls approximately 117,442 hectares of mineral tenure, including three groups of contiguous Crown-Granted mineral claims, such as the Cariboo Group, Island Mountain Group and Mosquito Creek Group, as well as a block of contiguous mineral tenures centered on the Town of Wells, which is located approximately 85 kilometers east of Quesnel, British Columbia. It currently has negative earnings.

The Company's QR Mine & Mill is located approximately 58 kilometers southeast of Quesnel, in the Cariboo Mining District, and is in close proximity to the Company's other mineral tenures.

Inovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology

Inovio Pharmaceuticals {NASDAQ: INO} have confirmed today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.'s assets, including pioneering needle-free jet injection technology, devices, and intellectual property.

Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration

Inovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology

PLYMOUTH MEETING, Pa. – May 2, 2016 – **Inovio Pharmaceuticals {NASDAQ: INO}** announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.'s assets, including pioneering needle-free jet injection technology, devices, and intellectual property.

This deal was first announced in a definitive agreement on March 14, 2016.

Inovio acquired BioJect for \$4.3 million in Inovio common stock and \$1.2 million in cash.

Inovio is advancing multiple novel cancer and infectious disease immunotherapies and vaccines as well as delivery devices to optimally administer them. Since administration of Inovio's products is a two-step process involving injection and electroporation delivery, it is also focused on enhancing ease and cost of administration to best serve clinical requirements. An integrated injection and electroporation device that eliminates needles and reduces disposable materials in an automated process would be a paradigm-changing step in vaccine administration in large populations.

Inovio has been developing needle-free electroporation technology that works on the surface of the skin. BioJect's needle-free jet injection technology uses high pressure gas or

springs to propel liquid medicine into skin. Its devices have demonstrated favorable utility, safety, and tolerability attributes in animals and humans. Under a prior research agreement Inovio tested the two separate technologies together and generated compelling antigen expression and immune responses in animals. Inovio will now combining the two technologies into one highly optimized integrated delivery device.

Dr. J. Joseph Kim, President and CEO, said, *"Inovio's current electroporation devices are underpinning important immunotherapy and vaccine products with clear clinical development paths and commercial opportunities. Our CELLECTRA® 5PSP device for intramuscular immunotherapy delivery, with its recently finalized commercial design, will be used in our cervical dysplasia phase III study for VGX-3100. Our intradermal delivery device, which facilitated recently reported robust immune responses from our Ebola vaccine, will be used to advance other infectious disease vaccine clinical development programs including the one we are preparing for Zika".*

"As we think long-term about broad market needs and new product opportunities, needle-free administration could help make potentially life-changing vaccines against critical infectious diseases more widely accessible globally. This newly acquired needle-free injection technology is an excellent addition in our product development vision and we look forward to fulfilling our vision for this optimized, highly automated needle-free delivery device."

Supporting the goal of non-invasive administration, the U.S. Army Small Business Innovation Research program recently granted Inovio \$500,000 to support the development of a

needle-free, non-invasive skin-surface electroporation device for DNA vaccine delivery.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACTS:

Bernie Hertel

Inovio Pharmaceuticals

+1 858 410 3101

bhertel@inovio.com

####

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties

inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that

may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Colonial Coal to raise \$2.4M, sell 10% of Flatbed property

Colonial Coal International Corp. {TSX.V: CAD} has recently entered into a new letter agreement with an investor group for a private placement into the company, and an agreement to purchase 10% of the Flatbed property.

The Flatbed property deal will become available after the finalisation of the private placement.

2016-05-02 11:55 ET – News Release

Mr. David Austin reports

PROPOSED PRIVATE PLACEMENT AND 10% FLATBED PROPERTY INTEREST ACQUISITION

Colonial Coal International Corp. {TSX.V: CAD} has recently entered into a new letter agreement with a certain investor group which provides for the terms and conditions of each of a proposed private placement of units of the corporation together with the corresponding agreement by the investor to acquire a 10-per-cent registered and beneficial ownership interest in the corporation's Flatbed property which will become available to the investor upon the successful completion of the private placement.

David Austin, the corporation's president and chief executive officer, stated: "I am very pleased that we have been able to re-establish a potential long-term partner for the development of the company's various property and business interests. We are hopeful that this partnership will continue to grow as Colonial Coal explores its many options going forward."

Private Placement

In conjunction with the proposed Private Placement the Corporation has agreed to sell 24,000,000 units (each a "Unit") of the Corporation; representing approximately 19.866% of the presently issued and outstanding common shares of the Corporation (each a "Common Share") as of the date hereof on a non-diluted basis; to the Investor at a price of \$0.10 per Unit for gross proceeds of \$2,400,000.

Each Unit is comprised of one Common Share and one Common Share purchase warrant (each a "Warrant") of the Corporation, with each such Warrant entitling the Investor to purchase an additional Common Share at an exercise price of \$0.20 per Common Share for a period of two years from closing of the Private Placement (the "Private Placement Closing"). The Private Placement is expected to close by May 9, 2016.

No finder's fees will be payable by the Corporation in connection with the completion of the Private Placement.

Closing of the Private Placement is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, inclusive of that of the TSX Venture Exchange (the "Exchange"). In accordance with the policies of the Exchange, the Corporation may be required to obtain disinterested shareholder approval (the "Disinterested Shareholder Approval") to the Investor becoming a "Control Person" (as defined by Policy 1.1 of the Exchange) by virtue of any Warrant exercise which would cause the Investor to hold more than 20% of the outstanding Common Shares. The Corporation shall attend to obtaining Disinterested Shareholder Approval as soon as reasonably practicable after the Private Placement Closing.

Acquisition

Upon the successful completion of the entire Private Placement Closing the Investor has agreed to acquire, within two business days of the Private Placement Closing, a 10% registered and beneficial ownership interest (the "10%

Interest"; both carried and then working (as described below)) in those certain coal licenses that together comprise the Corporation's Flatbed Property located in the Liard Mining Division in Northeastern British Columbia, Canada (collectively, the "Flatbed Property") for cash consideration of \$5,000,000 (the "Acquisition"); pursuant to the terms and conditions of a proposed form of "Mineral Property Acquisition and Joint Venture Agreement" which is set forth in Schedule "B" to the Letter Agreement (the "Acquisition Agreement"); it being acknowledged and agreed that the final form of Acquisition Agreement will be mutually agreed upon prior to the Private Placement Closing (collectively, the "Acquisition Closing"). The Acquisition is expected to close before by May 11, 2016.

Subsequent to the Acquisition Closing, such initial carried 10% Interest will be subject to straight line dilution upon the Company first funding and incurring, directly or indirectly, an aggregate of \$5,000,000 in exploration and development expenditures on the Flatbed Property, at which time the parties will form a joint venture for the purpose of carrying out further development work and production on the Flatbed Property (the "Joint Venture"); all pursuant to the terms and conditions of a proposed form of "Joint Venture Agreement" which is set forth in Schedule "C" to the proposed Acquisition Agreement; and which Joint Venture shall include, but not be limited to, the following provisions:

(a) the Company shall be the initial manager of the Joint Venture and the Company shall remain the manager as long as the Company has not less than a 50% participating interest in the Flatbed Property; (b) the operations of the Joint Venture shall be overseen by a management committee, with each party to have voting rights on such committee equal to their

participating interest in the Joint Venture. In the event that the parties' interests become equal, the manager shall have a casting vote; (c) the participating interests of the parties in the Joint Venture shall be subject to dilution for non-contribution to costs in proportion to their respective interests on a straight line basis and with an initial deemed cost basis of \$5,000,000 (that being as to \$4,500,000 for the Company and as to \$500,000 for the Investor); provided that should the Investor's participating interest, at any time, equal to or fall below 2%, then the Investor's then participating interest shall be deemed to be converted into a 2% net profits interest royalty (the "NPI Royalty"); as defined by Exhibit "D" to the proposed Joint Venture Agreement; and (d) the Company may elect at any time to purchase all or a portion of the NPI Royalty from the Investor for the sum of \$12,500,000 per each 1% of the NPI Royalty.

Other Transaction matters

Upon the successful completion of the Acquisition Closing, however, subject at all times to any prior suitability and filing requirements of the Exchange and all applicable securities laws and regulators, the Investor will be entitled to immediate appointment of two members (the "Appointees") to the Company's Board of Directors (the "Appointments") with one member of the Company's then Board of Directors resigning. In connection with such Appointments, the Company shall immediately grant to each of the Appointees, in accordance the provisions of the Company's Option Plan, a vesting (equally over 12 months) stock option to acquire up to 2,000,000 Common Shares at an exercise price of \$0.10 per Common Share (the "Option Price") for a period of five years from the date of such grant (the "Option"). In this respect the Parties acknowledge and agree that, in accordance with current Exchange policy and the provisions of the Company's Option Plan, the Option Price may be subject to adjustment upwards at

the time of the Option grant so as to ensure that the Option Price represents the Company's current market trading price at the time.

Upon the successful completion of the Acquisition Closing it is presently expected that Private Placement and the Acquisition proceeds will be utilized by the Company to complete the Company's planned and to be mutually agreed upon exploration program on its Flatbed Property and for Company general corporate and working capital purposes resulting therefrom.

All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance of the securities in accordance with applicable Canadian securities legislation. In addition, the securities referred to in this news release have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This news release shall not constitute an offer to sell or the solicitation or an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares and Warrants to be issued by the Corporation will be "restricted securities" as defined under Rule 144(a)(3) of the U.S. Securities Act.

We seek Safe Harbor.

Nymox director Robinson continues buying spree

Nymox Pharmaceutical Corp {NASDAQ: NYMX} Director James Robinson continued his recent buying spree by purchasing 15,000 more shares of the company.

It is heartening to see a director purchasing so much stock in a company, he is leading by example.

Nymox Pharmaceutical Corp {NASDAQ: NYMX} Director James Robinson bought 15,000 shares of Nymox Pharmaceutical Corp stock in a transaction dated Friday, April 29th.

The stock was purchased at an average cost of \$2.27 per share, with a total value of \$34,050.00.

Following the completion of the acquisition, the director now directly owns 2,762,550 shares in the company, valued at approximately \$6,270,988.50.

James Robinson also recently made the following trade:

On Friday, April 15th, James Robinson bought 39,500 shares of Nymox Pharmaceutical Corp stock.

Looming Zinc Supply Shortage Good News For Producers And Explorers

Stefan Ioannou of Haywood Securities is bullish for the price of zinc as a result of recent mine closures causing a supply deficit for the metal.

Ioannou predicts a recovery for the price of zinc faster than for other metals.

Zinc supply deficit looming, bullish for zinc miners.

The outlook for zinc appears bullish, says **Stefan Ioannou of Haywood Securities**, spearheaded by mine closures, dwindling production and the dearth of replacement projects.

This looming supply gap could mean increased zinc prices by the end of the year, explains Ioannou in this interview.

[To read the full article, please click HERE](#)

Inovio Partners with National Cancer Institute to Initiate Hepatitis C Immunotherapy Clinical Trial

Inovio Pharmaceuticals {NASDAQ: INO} has announced they have partnered with the National Cancer Institute and the Mayo Clinic to initiate a Hepatitis C immunotherapy trial.

DNA based immunotherapy will be tested for safety and immune responses.

The object is to eliminate Hepatitis C.

Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial

DNA-based immunotherapy will be tested for safety and immune responses in quest to eliminate HCV infection

PLYMOUTH MEETING, Pa. – April 27, 2016. Inovio Pharmaceuticals {NASDAQ: INO}) announced today its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments.

The study will enroll patients who are in the early stages of chronic HCV infection to determine the therapy's ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability. In this dose-

escalation study INO-8000 will be combined with increasing doses of DNA-based IL-12 (INO-9012), an immune activator, which in previous studies has been shown to increase the therapeutic immune response to DNA immunotherapies.

The study is funded by the National Cancer Institute's Division of Cancer Prevention and will be conducted at the Mayo Clinic and other U.S. sites.

Among those initially infected with HCV, 75 to 85 percent will go on to develop chronic illness. More than 170 million people around the world are chronically infected with HCV. According to the U.S. Centers for Disease Control (CDC) an estimated 3.5 million people in the US are chronically infected with HCV, with about 20,000 new cases of chronic HCV reported in the US in the last year. About 15,000 people in the US die each year of HCV-related causes.

Inovio's SynCon® DNA immunotherapy, INO-8000, is encoded for the antigens NS3/4A, NS4B, and NS5A of HCV genotypes 1a and 1b, the most difficult-to-treat genotypes. The product is designed to induce robust T cells to eliminate cells displaying these antigens and has been shown in published preclinical studies to generate powerful HCV-specific T cell responses throughout the body and in the liver.

Dr. Jeffrey Jacobson, the study's Principal Investigator, said *"Development of a vaccine therapy against hepatitis C would be important as a less expensive, simpler treatment alternative to several months of medication that should encourage better patient compliance, particularly in difficult-to-treat patient*

populations. It also holds the promise of inducing immunity protective against re-infection in patients who continue to be exposed, a not uncommon problem.” Dr. Jacobson is Professor of Medicine, Neuroscience and Neurovirology at the Lewis Katz School of Medicine, Temple University.

Dr. J. Joseph Kim, President and CEO, said, *“Despite recent treatment advances, HCV infection remains a burden on our healthcare and payor system and continues to spread. Today’s expensive drugs are highly effective in treating HCV but are not available to the majority of infected individuals. We are pleased to join the NCI and Mayo Clinic in this quest to develop an alternative medical solution to fight this disease, which remains one of the fastest-developing markets in healthcare.”*

Inovio previously announced that it signed a collaborative agreement with GeneOne Life Sciences to develop INO-8000, along with a DNA IL-28 immune activator, in drug-resistant HCV patients in a phase I study in Korea. That study is on-going.

About Hepatitis C

Hepatitis C is a contagious liver disease that ranges in severity from a mild illness lasting a few weeks to a serious lifelong illness that attacks the liver. It results from infection with the hepatitis C virus, which is spread primarily through contact with the blood of an infected person. Hepatitis C can be either “acute” or “chronic.” Acute hepatitis C virus infection is a short-term illness that occurs within the first six months after someone is exposed to the virus. For most people, acute infection leads to chronic infection, which can last a lifetime and lead to serious liver

problems including cirrhosis (scarring of the liver) or liver cancer.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline.

Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACT:

Bernie Hertel

Inovio Pharmaceuticals

+1 858 410 3101

bhertel@inovio.com

####

This press release contains certain forward-looking statements

relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and

whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Kootenay Silver investor Pan American Silver adds to maintain their 10% investment

Kootenay Silver Inc. {TSX.V: KTN} and **Pan American Silver Corp. {TSX: PAA}** have announced that Pan American intend to subscribe for 6,793,550 additional Kootenay shares in order to maintain their 10% holding in the company.

This will bring in around CAD \$1.5 million into Kootenay's treasury.

VANCOUVER, April 26, 2016 **Kootenay Silver Inc. {TSX.V: KTN}** and **Pan American Silver Corp. {TSX: PAA}** are pleased to announce that, following the issuance of Kootenay's common shares as consideration for Kootenay's acquisition of Northair Silver Inc. (see Kootenay press release dated April 21, 2016) as well as Kootenay's acquisition of the two and a half percent (2.5%) net smelter returns royalty from Coeur Capital, Inc. with respect to the future production of Kootenay's La Cigarra project (see Kootenay press release dated March 29, 2016), Pan American has exercised its second tranche option to subscribe for additional common shares of Kootenay in order to maintain a ten percent (10%) ownership interest in Kootenay's issued and outstanding shares (see Kootenay press release dated February 26, 2016) (the "Second Tranche Option") in accordance with the Subscription Agreement dated February 15, 2016 entered into between Pan American and Kootenay, as amended (the "Subscription Agreement"). As a result, Pan American intends to subscribe for 6,793,550 additional Kootenay common shares for an aggregate subscription price of CAD\$1,553,431 (the "Subscription Price").

Transaction Details

The Subscription Price for the exercise of the Second Tranche Option consists of the following:

Pan American's subscription for 5,723,550 common shares of Kootenay at the subscription price of CAD\$0.22 per Kootenay common share for gross proceeds of CAD\$1,259,181;

and

Pan American's subscription for 1,070,000 common shares of Kootenay at the subscription price of CAD\$0.275 per Kootenay

common share for gross proceeds of CAD\$294,250

(the "Second Tranche Investment").

The closing of the Second Tranche Investment is subject to certain standard conditions precedent for financings of this nature set out in the Subscription Agreement, including approval and acceptance by the TSX Venture Exchange.

Kootenay intends to use the net proceeds of the Second Tranche Investment for exploration activities and general corporate purposes.

Kootenay President and CEO James McDonald stated: *"We are delighted with Pan American's vote of confidence in not only our Promontorio Mineral Belt assets, but also the La Cigarra opportunity we have acquired through the business combination with Northair Silver Inc. After the closing of the Second Tranche Investment, we will have a strong cash position to advance the La Cigarra project and pursue more potential consolidation and growth opportunities that will be accretive to the Kootenay shareholders."*

About Kootenay

Kootenay Silver Inc. is an exploration company actively engaged in the discovery and development of mineral projects in the Sierra Madre Region of Mexico and in British Columbia, Canada. The Company's top priorities are the advancement of the La Cigarra silver project and the Promontorio Mineral Belt, in Chihuahua, Mexico and Sonora, Mexico (respectively).

The La Cigarra property is 26 kilometres from the historic mining city of Parral and boasts nearby power, good road access, gentle topography, and established infrastructure. La Cigarra currently hosts a resource estimate of 51.47 million ounces of silver in the Measured & Indicated categories grading 86.3 g/t silver and 11.46 million ounces of silver in the Inferred category grading 80 g/t silver. The mineralised system at La Cigarra has been traced over 6.5 kilometres and is defined at surface as a silver soil anomaly and by numerous historic mine workings. The La Cigarra silver deposit is open along strike and at depth and is approximately 25 km north, and along strike, of Grupo Mexico's Santa Barbara mine and Minera Frisco's San Francisco del Oro mine.

The Promontorio Mineral Belt includes Kootenay's La Negra high-grade silver discovery and its Promontorio Silver Resource. Kootenay's core objective is to develop near term discoveries and long-term sustainable growth. Management comprises of proven professionals with extensive international experience in all aspects of mineral exploration, operations and venture capital markets.

Qualified Person

The Kootenay technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 (Standards of Disclosure for Mineral Projects) and reviewed on behalf Kootenay by James McDonald, P.Geo, President, CEO & Director for Kootenay, a Qualified Person.

Poet Technologies to acquire Singaporean photonics outfit DenseLight Semiconductors

POET Technologies {TSX.V: PTK} has announced the acquisition of DenseLight Semiconductors, of Singapore, in a cash plus shares transaction.

DenseLight are a private company with existing cashflow and modest profits.

Comment

So we find out what caused the shareprice to spike a few days ago leading to the stock having to be halted!

POET are currently down around 10% after resumption of trading after this news release, so some of those buying on the knowledge news was imminent have suffered a short term loss. No sympathy from this quarter, that should not have happened.

This deal values POET at \$1 per share, which is what is probably causing the current reversal in the price.

The deal looks a good fit, prima facie, in that it gives them access to some cashflow, established test and development facilities, and channels to market..

What I see as the major benefit here is the deal gives them access to a laboratory and wafer development facilities, and to skilled employees at is what is probably no more than a mid priced salary economy.

They also gain channel distribution networks, essential if they are to expand and develop new products.

The cost of this is around CAD \$15,700,000 in shares and cash.

POET will fund the cash element from their existing treasury, but I would expect they may have to top up at some point, so I wouldn't rule out a financing in due course, if not sooner if the shareprice holds firm.

News Release

POET TO ACQUIRE DENSELIGHT SEMICONDUCTORS

16-04-28 – **Poet Technologies In {TSX.V: PT}** has signed a definitive agreement to acquire all the shares of DenseLight Semiconductors Pte. Ltd., a private designer, manufacturer and provider of photonic sensing and optical light source products.

Upon completion of this transaction which is subject to applicable regulatory reviews and approvals, including approval of the TSX Venture Exchange, POET will own 100% of DenseLight and its global photonics business and assets, including fabrication facility, intellectual property and technologies.

DenseLight, a Singapore-based privately held photonics company, designs, manufactures, and delivers leading photonic optical light source products and solutions to the communications, medical, instrumentations, industrial, defense, and security industries. DenseLight processes III-V

based optoelectronic devices and photonic integrated circuits through its in-house wafer fabrication and assembly & test facilities. The company is recognised worldwide for its technological innovations in high performance semiconductor infrared super-luminescent light sources and lasers, with a proven track record in deployed applications.

This revenue accretive acquisition of DenseLight will provide POET with a fab infrastructure for future product development, access to product sales and channel distribution networks and a broader product portfolio of photonic products. Collectively this will enable POET to better service the end to end Data Communications market.

Additionally, POET expects to gain intellectual property and know how that will enhance its presence in the fast growing Telecom Access Network markets for Passive Optical Networks (PON) and in other markets complementary to Data Communications.

POET intends to continue and expand the operation of DenseLight's existing manufacturing facilities in Singapore. DenseLight's operations had generated revenues of US\$2.6 Million in 2015 with a consistent gross profit in excess of 40% in each of the 3 previous years. POET anticipates that DenseLight as a division will achieve positive net income by fiscal 2017.

This strategic acquisition will result in many ancillary benefits to the combined company. DenseLight's test and reliability capabilities will be particularly valuable in

accelerating New Product Introduction (NPI). Additionally, POET expects to benefit from access to DenseLight's proven and seasoned engineers and other employees.

DenseLight's location will substantially increase supply chain efficiencies as current suppliers are located within the same geographic zone, facilitating ease of communication, interaction and real time testing on future and current product development.

POET is also benefiting from the fruits of an investment in excess of (S) \$50 Million that has been made to date by the DenseLight shareholders to enhance the company's core competencies. While DenseLight is a strategic acquisition, the Company is also engaged in advanced stages of other avenues that it expects will accelerate the path to revenue over the next 12 months and further POET's monetisation strategy.

*"The acquisition of DenseLight Semiconductor reflects a new chapter in our history, and serves as a significant step in realizing the promise of our product roadmap and strategic plan we established in September 2015," said **Dr. Suresh Venkatesan, POET's Chief Executive Officer**. "This synergistic combination can provide our customers a broader range of differentiated photonics technologies. The resulting enhancement of our design, test and packaging capabilities also promises to optimize time-to-revenue for our customers. POET now has a larger product portfolio to enhance our mission of enabling integrated photonic products for our expanded end markets."*

*“DenseLight is tailor-made to solidify POET’s goal of attaining a leadership position in III-V integrated opto-electronics technology development and manufacturing,” said **Jerry Rodrigues, Chairman and Chief Executive Officer of DenseLight Semiconductors.** “We at DenseLight are delighted to be an integral part of the POET family and to play a strategic role in the Company’s growth plans in the rapidly developing III-V integrated opto-electronics market and particularly the exciting application demands for the Internet of Things (IOT). We are excited by the opportunities ahead of us and look forward to working closely with POET management to return stronger financial results and meaningful shareholder value.”*

Terms and Structure of the Transaction

POET is executing this acquisition via a combination of stock and cash – a significant portion of the cash will be used to repay DenseLight’s outstanding debt and other liabilities. The amounts to be paid are subject to customary adjustments. POET expects to fund the purchase price of the acquisition with its cash on hand.

The DenseLight shareholders will be issued at the Closing, a number of shares of common stock (the “POET Shares”) representing ten and one-half million dollars (U.S.) (\$10,500,000) in value based on a deemed price for such POET Shares of the U.S. equivalent of one Canadian dollar (CDN\$1). In addition, additional POET Shares representing one million dollars (U.S.) (\$1,000,000) based on the same equivalent share price will be issued to the DenseLight shareholders in the event that DenseLight meets or exceeds a pre-determined revenue target during calendar 2016.

All salaries, fees or debts of any kind owing by DenseLight to management shareholders and accrued or incurred prior to 2016, and past due obligations owed to current and past DenseLight employees, will be surrendered and cancelled at the Closing. In return, it is anticipated that, on an operational basis, the current and past employees will receive POET shares and cash on a settled basis. The sum total of POET Shares issued to cover debt will be the equivalent of about (S) \$ 2,537,368 in addition to about (S) \$1,689,353 in cash to be paid over a 9 month period. At the time of the closing of the transaction ("Closing"), DenseLight shall have no outstanding indebtedness on its balance sheet.

The issuance of the POET Shares must be in compliance with all United States and Canada Federal and State or Provincial securities laws and regulations, and the rules of the TSX Venture Exchange. The POET Shares will be restricted and subject to resale restrictions as established by the TSX Venture Exchange and U.S. Securities laws, including shares issued to non-management shareholders of DenseLight in satisfaction of outstanding indebtedness. All management shareholders of DenseLight shall agree not to sell, transfer, pledge or otherwise dispose of the POET Shares for a period of six months, at which time such shareholders may each sell up to 25% of the POET Shares received by them. Management Shareholders may sell an additional 25% of the POET Shares received by them after twelve months. Thereafter, all management shareholders shall be able to sell the remaining shares after 24 months from Closing. All non-management shareholders of DenseLight shall agree not to sell, transfer, pledge or otherwise dispose of the POET Shares received by them for six months, at which time such shareholders may sell up to 25% of the POET Shares received by them. Thereafter, such non-management shareholders may sell the remaining shares after 12 months from Closing.

POET Investor Town Hall Meeting in Toronto, Canada

Closing of the transaction is expected to be on or before May 10, 2016, subject to fulfillment of all conditions in the Agreement. Following Closing, POET will hold a live Town Hall Meeting for their shareholders, stakeholders and Analysts in Toronto to explain the strategic vision behind the acquisition and provide details on the integration of this transaction into the POET roadmap.

It is anticipated that the Town Hall Meeting will be held on May 16, 2016.

Further details will be announced when confirmed.

Inovio Pharmaceuticals to Report Q1 2016 Financial Results

Inovio Pharmaceuticals {NASDAQ: INO} have announced that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 14.30 p.m. GMT.

A live webcast is available for those wishing to participate.

Inovio Pharmaceuticals to Report First Quarter 2016 Financial Results May 9, 2016

PLYMOUTH MEETING, Pa. – April 26, 2016 – **Inovio Pharmaceuticals {NASDAQ: INO}** announced today that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 14.30 p.m. GMT.

A live and archived version of the audio presentation will be available online at <http://www.investorcalendar.com/IC/CEPage.asp?ID=174947> as well as through the “Webcast” tab on Inovio’s home page at www.inovio.com

This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible two hours after the call at +1 201 612 7415 using passcode 13635656.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio

of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACT:

Bernie Hertel,

Inovio Pharmaceuticals

+1 858 410 3101

bhertel@inovio.com

####

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or

be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will

be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Barkerville Gold Mines Closes \$15.5 Million Bought Deal Private Placement

Barkerville Gold Mines {TSX.V: BGM} have confirmed they have closed the previously announced bought deal placement.

BGM have raised CAD \$15.5 million issuing 22.1 million flow through shares at 70c per share.

Comment

Great news for Barkerville holders, as this money is raised via a flow through, all \$15million has to be spent in the ground!

It is law in Canada that all flow through money is spent on exploration, there are severe penalties for non compliance, and all participants in the financing would have to change their tax returns, and incur more taxes!

Imagine what sort of drill campaign they will run with this sort of treasury available!

Newsflow could be considerable starting in a few months time.....

Barkerville Gold Mines Closes \$15.5 Million Bought Deal Private Placement

TORONTO, Ontario, April 26, 2016 – **Barkerville Gold Mines Ltd. {TSX.V: BGM}** is pleased to announce that it has closed its previously announced bought deal private placement, led by Haywood Securities Inc. with a syndicate including Sprott Private Wealth L.P. (collectively, the “Underwriters”).

The Company issued an aggregate of 22,183,500 flow-through common shares at a price of \$0.70 per Flow Through Share for aggregate gross proceeds of \$15,528,450.

The Company paid the Underwriters a cash commission equal to 6% of the gross proceeds of the Offering, not including gross proceeds raised from investors on the president’s list and issued an aggregate of 404,200 compensation options to the Underwriters.

Each Compensation Option entitles the holder to acquire one common share of the Company at a price of \$0.70 until April 26, 2018.

The Company intends to use the net proceeds from the Offering to incur Canadian exploration expenses that are “flow-through mining expenditures” (as such terms are defined in the Income Tax Act (Canada)) (the “Qualifying Expenditures”) on its

extensive property package encompassing the Cariboo Mining District and related properties in British Columbia.

The Qualifying Expenditures will be renounced to the subscribers with an effective date no later than December 31, 2016.

The securities issued pursuant to the Offering will be subject to a statutory four month hold period.

The securities offered have not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

For further information please contact:

Tom Obradovich. President & CEO

+1 416 361 2511

tobradovich@barkervillegold.com

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company's objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

POET Technologies halted by the company pending news

POET Technologies {TSX.V: PTK} have been halted from trading at the request of the company pending news.

The halt was called at 10.52 am yesterday, after the share price had risen 25% in two and a bit trading sessions, on the back of strong volume.

POET Technologies trading halt pending a news release.

POET Technologies {TSX.V: PTK} has requested a trading halt "pending a news release".

This seems to have been prompted by a 25% rise in just over two trading sessions, on strong volume, and no news announced. Maybe there has possibly have been a leak somewhere?

Recently POET has traded around 300,000 shares per day, with the odd high volume day, and a few low volume ones. On the 21st April, the volume was 487,000 and the share price rose 5c, then on the 22nd April the volume was 971,000 and the share price rose 6c, with the high volume and strong rise a big clue something was about to occur.

The value of trades in two days was over CAD\$1,500,000, quite a sum in a relatively quiet market.

Yesterday, the stock was halted at 10.52 am, and there had already been 343,000 shares traded, and the share price was up another 10%!

Let's hope there is something tangible to back up this rise, but the high volume and 25% price rise in a little over two trading sessions suggests some people already think they know!

We await the anticipated news with baited breath.

The TSX Venture Exchange has

over 900 “zombie” companies

The **TSX Venture Exchange** is overrun with more than 900 “zombie” companies with negative working capital, according to a new study.

The research comes from Tony Simon, co-founder of the Venture Capital Markets Association.

Zombie companies threaten the credibility of the TSX.V

Research by a frequent critic of the TSX, Tony Simon, highlights the farce of companies with no money, and no prospects of raising much money, maintaining a listing on the exchange.

The suspicion is that the exchange is happy to collect the fees and are ignoring the criticism being directed at them over this.

[To read the full article, please click here](#)

Range Energy closes first tranche of recently announced placing

Range Energy Resources {CSE: RGO} have confirmed they have received the first tranche of the recently announced non brokered private placement.

Vancouver, BC, Canada – **Range Energy Resources {CSE: RGO}**) is pleased to announce that further to its news release dated April 11, 2016, the Company closed the first tranche of the non-brokered Private Placement for a total of 18,836,000 units (the “Units”) of the Company at a price of CDN \$0.035 per Unit for gross proceeds of approximately CDN \$659,260.00.

Each Unit consists of one (1) common share and one (1) transferrable share purchase warrant. Each warrant entitles the holder thereof to purchase one (1) additional common share of the Company on or before April 15, 2021 at a price of CDN\$0.05 per common share.

The securities issued are subject to a four (4) month hold period that expires on August 16, 2016.

The Company paid a finders' fee of \$10,500.00 (5% on \$210,000.00) and 300,000 finder's warrants (5% on 6,000,000 Units). Each finders' warrant entitles the finder to purchase one (1) common share of the Company on or before April 15, 2017 at a price of CDN\$0.05 per common share.

The capital from the Offering will be used by the Company to continue to fulfill its obligations to joint venture participants so that the development of the Khalakan Block in the Kurdistan Region of Iraq can continue as well as provide general working capital.

For further information on Range Energy Resources Inc., please visit the Company's web site at www.rangeenergyresources.com

On Behalf of the Board of Directors:

Toufic Chahine

Chairman

+1 604-687-2038

range@rangeenergyresources.com

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

This news release contains certain statements that may be deemed to include “forward-looking statements”. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Range Energy believes the expectations expressed in such forward

Neometals performs strongly as quality mining stocks move up

Neometals {ASX: NMT} is an example of a quality mining stock, on the cusp of production, and its share price is performing very strongly versus its peers.

Investors are cautiously returning to the sector, but are being selective about the stocks they are prepared to invest in.

Mining investors are returning. but are being selective.

If proof were needed that mining investors are returning to the market, then the recent strong advance in the TSX Venture Exchange, heavily laden with junior miners, is the leading indicator.

Some stocks are moving up, but many are still stuck in the doldrums, with few friends and even fewer buyers. These are generally the early stage greenfield explorers of some moose pasture up in the Yukon, where drilling only takes place a few months a year due to the incredibly inclement weather that prevails there.

A huge divide has opened up between the mining companies producing or financed to production, and the explorers, who will return for fundraising after fundraising, diluting their shareholders in the process, whilst management continue to reward themselves handsomely in the form of salaries and options. That game seems to be done, for now at least.

An example of a quality management team and project is **Neometals {ASX: NMT}**, whose shareprice has risen from 30c to 45c recently, as their project moves into production. and they conclude deals that are putting significant cash deposits into their bank account.

Other companies we are watching that have moved up strongly recently include **Condor Gold {AIM: CNR}**, and **Barkerville Gold {TSX.V: BGM}**. Mexican silver exploration company **Kootenay Silver {TSX.V: KTN}** has also doubled since January, after concluding a couple of very nice deals that ensure the future of the company.

The common denominator is that these companies have solid projects and good management teams, and the market recognises this, and their share prices are rising accordingly.

So selective investment is the new norm for now, find a company that is either producing or very close to production and financed into production, and the market will respond. The alternative is to be continually diluted whilst management continue to draw their salaries and little or no money goes into the ground where it may create shareholder value!

Barkerville Gold Mines corporate update plus exploration and production plans

Barkerville Gold Mines {TSXV: BGM.V} has announced a corporate update.

It has also announced an update on its forthcoming exploration program and small-scale production plans, as well as a summary of recent activities with respect to optimising the Cow Mountain Resource.

Barkerville Gold Mines Provides Outlook and Corporate Update for 2016

April 21st, 2016

TORONTO, ON – **Barkerville Gold Mines {TSXV: BGM.V}** is pleased to provide an update on its forthcoming exploration program

and small-scale production plans, as well as a summary of recent activities with respect to optimizing the Cow Mountain Resource.

Production at Bonanza Ledge and BC Vein

In the first quarter of 2016, Barkerville completed an underground mine plan for the balance of Bonanza Ledge ore and development of BC Vein ore which will be accessed from the same infrastructure. Geo-technical drilling was also completed on Bonanza Ledge.

This plan will be submitted to the BC Ministry of Energy and Mines ("BCMEM") this quarter. Tenders have been submitted to several mine contractors and environmental work is also underway with underground development planned by the third quarter 2016. Upgrades and maintenance continues at the Company's QR Mill where the ore will be processed. Details on production will be provided upon approval of the mine plan and environmental studies by the BCMEM.

Exploration 2016

The Company added over 80,000 hectares of additional exploration lands to its current extensive property package in the Cariboo Mining District in Q1. After a detailed regional and localised evaluation by our exploration team, a substantial drilling program on Island Mountain adjacent to the Cow Mountain Resource was recommended. In addition, an airborne geophysical magnetic and electromagnetic survey has been tendered and will commence in Q2, along with geochemical surveys, geological mapping, and prospecting. Priority targets generated from this program will be drill tested in the latter part of 2016.

Cow Mountain Update

Further to the company's news release dated March 31, 2015, the Multiple Indicator Kriging (MIK) Cow Mountain resource estimate performed by Snowden Mining Industry Consultants of Vancouver, B.C. reported an Indicated Resource of 2.8 M oz (35.8 M tonnes at 2.4 g/t gold) and Inferred Resources of 2.0 M oz (27.5 M tonnes at 2.3 g/t gold) at a 0.5 g/t gold block cut-off.

The Company's technical staff, as well as third party consultants, have been recompiling and validating the Cow Mountain databases with the aim of establishing a robust, geologically constrained resource model on which future economic considerations will be based. This new, geologically controlled estimate is scheduled for completion in the third quarter of 2016.

Alongside the aforementioned studies, the Company has recently completed 18,357 metres of its Phase I diamond drilling program on Cow Mountain designed to upgrade Inferred and Indicated gold resources within a conceptual open pit. Drilling has been halted temporarily due to seasonal melt conditions and the Phase II campaign is scheduled to begin once environmental conditions allow. The 41,000 metre Phase II program will take into account results from Phase I and will be utilized to further optimise the economics of the conceptual open pit. The second phase will also encompass geotechnical drilling for the purposes of optimizing pit walls as well as collection of fresh material for detailed metallurgical test work.

Qualified Persons

Exploration activities at the Cariboo Gold Project are jointly

administered on site by the Company's Project Managers Maggie Layman, P.Geo. and Wanda Carter, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

For further information on Barkerville Gold Mines Ltd., please contact:

Tom Obradovich

CEO

+1 416 361 2511

tobradovich@barkervillegold.com

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, uncertainty over the outcome of any litigious matters, the Company's objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could

cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Price of oil expected to remain low after production freeze talks fail

The price of oil has fallen back after the failure of talks to establish a freeze on production unsurprisingly failed.

The main problem is that Iran is being asked to agree a freeze at January levels, when theirs was low due to sanctions, whereas Saudi Arabia and Russia produced at record levels.

Neometals and partners complete proprietary processing technology agreement.

Neometals Ltd {ASX: NMT} and their partners have completed the agreement agreed in December 2015 in respect of their proprietary processing technology agreement.

This is consistent with Neometals' strategy to develop and hold a portfolio of royalty interests from sub-licensing the technology.

Exclusive licence of proprietary processing technology

Neometals Ltd {ASX: NMT} refers to its announcement dated 10 December 2016 that it had entered into a binding term sheet for a global (*) exclusive licence of proprietary technology for the extraction and recovery of minerals and metals.

Neometals is pleased to advise that the relevant parties have entered into the formal agreements contemplated by the term sheet. The formal agreements set out the detailed arrangements under which Neometals' subsidiary, Alphamet Management Pty Ltd, is responsible for managing the commercialisation and development of the technology, with all revenue received from the commercialisation to be split 25:75 between Alphamet and the owners of the technology.

Neometals' current non-exclusive licence of the technology for the Barrambie Project has been transferred into the new arrangements, effectively reducing the technology royalty cost to the project from 5% to 3.75%.

Neometals and Alphamet have additionally entered into a strategic alliance with Sedgman Ltd. with a view to providing a platform for the commercialisation of the technology. Alphamet and Sedgman will work together to identify opportunities and execute the implementation of the technology, as part of Neometals' strategy to develop and hold a portfolio of royalty interests from sub-licensing the technology.

(*) Worldwide excluding China and Russia, and also excluding certain provinces in Canada for so long as an existing licence of the technology in respect of those provinces remains in place.

For further information, please contact:

Chris Reed
Managing Director
Neometals Ltd.
+61 8 9322 1182
info@neometals.com.au

Nymox Director Robinson buys 39,500 shares

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} director James Robinson has purchased 39,500 shares, adding to his substantial holding in the company.

Robinson has been buying on a regular basis recently

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} director James Robinson has purchased 39,500 shares, adding to his substantial holding in the company.

Robinson purchased the stock at an average price of \$2.39 per share, costing him \$94,405.00.

James Robinson now holds 2,722, 550 shares.